Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA.
Davina GaleAndrew R J LawsonKaren HowarthMikidache MadiBradley DurhamSarah SmalleyJohn CalawayShannon BlaisGreg JonesJames ClarkPeter DimitrovMichelle PughSamuel WoodhouseMichael EpsteinAna Fernandez-GonzalezAlexandra S WhaleJim F HuggettCarole A FoyGerwyn M JonesHadas Raveh-AmitKarin SchmittAlison DevonshireEmma GreenTim ForshewVincent PlagnolNitzan RosenfeldPublished in: PloS one (2018)
These studies demonstrate that eTAm-Seq technology is a robust and reproducible technology for the identification and quantification of somatic mutations in circulating tumor DNA, and support its use in clinical applications for precision medicine.